Ovid Therapeutics Inc.
OVID · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $132 | $6,272 | $130 | $76 |
| % Growth | -97.9% | 4,724.6% | 71.1% | – |
| Cost of Goods Sold | $17 | $0 | $0 | $0 |
| Gross Profit | $115 | $6,272 | $130 | $76 |
| % Margin | 87.1% | 100% | 100% | 100% |
| R&D Expenses | $5,853 | $6,465 | $6,659 | $5,923 |
| G&A Expenses | $0 | $4,880 | $6,021 | $6,775 |
| SG&A Expenses | $6,785 | $4,880 | $6,021 | $6,775 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | -$1,900 |
| Operating Expenses | $12,638 | $11,345 | $12,680 | $10,798 |
| Operating Income | -$12,523 | -$5,073 | -$12,550 | -$10,722 |
| % Margin | -9,487.1% | -80.9% | -9,653.8% | -14,107.9% |
| Other Income/Exp. Net | $365 | $389 | $2,315 | $1,469 |
| Pre-Tax Income | -$12,158 | -$4,684 | -$10,235 | -$9,253 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$12,158 | -$4,684 | -$10,235 | -$9,253 |
| % Margin | -9,210.6% | -74.7% | -7,873.1% | -12,175% |
| EPS | -0.17 | -0.066 | -0.14 | -0.13 |
| % Growth | -158% | 52.9% | -7.7% | – |
| EPS Diluted | -0.17 | -0.066 | -0.14 | -0.13 |
| Weighted Avg Shares Out | 71,110 | 71,110 | 71,045 | 71,010 |
| Weighted Avg Shares Out Dil | 71,110 | 71,110 | 71,045 | 71,010 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $17 | $99 | $141 | $160 |
| EBITDA | -$12,141 | -$4,974 | -$12,409 | -$10,762 |
| % Margin | -9,197.7% | -79.3% | -9,545.4% | -14,160.5% |